Previous 10 | Next 10 |
Allelica Collaborates with Invitae to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer PR Newswire Allelica and Invitae aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the lif...
Invitae is one of the worst-performing stocks in Cathie Wood's Genomic Revolution ETF, down over 90% from the highs of $56.60 set in December 2020. The stock has become so cheap it now trades at under half of the book value and roughly 2.4x sales, despite massive revenue growth over t...
2022 has been rough for many previous market darlings. Investors have moved to higher ground, deserting growth stocks in exchange for large, stable companies. However, savvy healthcare investors should treat this pullback as a buying opportunity. We'll look at two healthcare stocks that cou...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vale S.A. ( VALE ) – A victim of systemic headwinds in the metals sphere. Its stock is oversold, but undervalued. Pure Storage ( PSTG ) – Its enterprise-driven solutions provide superior ro...
Invitae to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022 PR Newswire SAN FRANCISCO , April 20, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report i...
Invitae announced the intention to shift the focus from external capital-fueled growth to self-funding. The company targets positive operating cash flow in the mid-term. To achieve that, the company will need to improve in some areas. Among them is the two-year $3 billion acquisit...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Small cap growth stocks entered bear market territory dur...
I started (growth) investing in early 2020 with the intention to buy and hold. In hindsight this was a mistake: the last bit of my Cathie Wood-esque 3-bagger in 2020 has completely disappeared in the last few months. Since I didn’t capitalize on the COVID-19 bubble (“...
Invitae (NYSE:NVTA) announced the commercial launch of its Neurodevelopmental Disorders (NDD) testing package for children with developmental disabilities. The company said the package includes three tests - chromosomal microarray analysis, analysis for fragile X-related disorders, and a...
Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders PR Newswire – First to offer suite of tests in easy to access format for children with developmental disabilities – SAN FRANCISCO , April 4, 2022 ...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...